Official Title A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)

Purpose

This study is testing a medicine called teplizumab to see if it can help people aged 18 to 25 who were recently diagnosed with Type 1 Diabetes (T1D). The goal is to find out if teplizumab can protect the cells in the body that make insulin, which helps control blood sugar.

People with T1D usually lose these insulin-producing cells over time, and this study wants to see if teplizumab can slow down or stop that process. Everyone in the study will continue using insulin as usual, but some will also get teplizumab (or a placebo, which has no medicine) through IV infusions.

Researchers hope this treatment will:

• Help the body keep making some of its own insulin

• Reduce the amount of insulin people need to take

• Improve blood sugar control

• Lower the risk of very low blood sugar levels

The study will last about 84 weeks (a little over a year and a half), and participants will have regular checkups and tests to see how well the medicine works and how safe it is.

Could this study be right for you?

• Must be diagnosed with Type 1 Diabetes in the past 2 months
• Must have had a positive test for at least one Type 1 Diabetes antibody
• For female participants of childbearing potential - must use a contraception method (or abstinence) 

Age Range

18 - 25 years

Contact Information

Ohio State University Wexner Medical Center

Lindsey Aldrich

lindsey.aldrich@osumc.edu

614-814-0772

Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

Purpose

This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.

People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 4 or more observable focal seizures per month
2. Taking at least 1 and up to 3 anti-seizure medications
3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months
4. Between the ages of 18 to 75

Age Range

18 - 75 years

Contact Information

300 W 10th Ave, Columbus, OH, 43210

Emily Huber

emily.huber@osumc.edu

614-814-1120

Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Purpose

In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use.  People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 3 PGTCS in an 8-week period
2. Have tried at least 2 anti-seizure medications without success
3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months
4. 18 years old and up

Age Range

18 years and up

Contact Information

300 W 10th Ave, Columbus, OH, 43210

Emily Huber

emily.huber@osumc.edu

614-814-1120

Official Title The Foods and Oils to Repair Correct and Enhance Strength (FORCES) Study: Determining the effect of dietary oils on muscle function, strength and mass

Purpose

The purpose of the FORCES Study is to determine how dietary oils effect muscle function, strength and mass in older adults who feel their muscle function and strength has declined with age.

During this 27-week study participants will

•  Consume ~2.5 tsp of oil each day through foods

• Complete muscle function and strength testing

• Have their blood drawn

• Have their body weight and composition measured

• Have an MRI scan of your legs, if able

• Fill out questionnaires

• Collect a small amount of muscle tissue from the leg (muscle biopsy

Could this study be right for you?

Feel your muscle function, strength or mass as decreased with age

Do NOT have food allergies 

Are not taking any weight loss medications or following a weight loss program

Age Range

65 - 80 years

Contact Information

The Ohio State University Columbus Campus

Rachel Cole

belurylabstudies@osu.edu

614-247-8235

Official Title Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to Immunotherapy

Purpose

This study will look at if a ketogenic diet (KD) can help treatment work better in patients with metastatic melanoma or metastatic kidney cancer. People who take part in the study will be randomly assigned to either continue eating their usual diet or trying the KD diet for 24 weeks. Participants will have blood and stool samples collected during the study. They will also test their sugar by doing daily glucose fingers sticks. Participants may be paid up to $200 for taking part in the study.

Could this study be right for you?

1. Patients with metastatic melanoma receiving first-line treatment with immunotherapy or Patients with metastatic renal cell cancer receiving first line treatment with immunotherapy.
2. Willing to give three stool samples
3. Willing to participate in a ketogenic diet (KD)

Age Range

18 years and up

Contact Information

The Ohio State University

Helena Gastier

_JOC-NTresearch_@osumc.edu

614-257-3434

Official Title The Knowledge and Perceptions of Gen Zs Regarding the Dietary Guidelines for Americans

Purpose

1. Use ideas from Social Cognitive Theory to describe Gen Zs regarding the Dietary Guidelines for Americans (DGA) 2020 to 2025
2. Explain what Gen Z knows and believes regarding the MyPlate recommendations for healthy eating related to:

• Filling half their plate with fruit and vegetables
• Filling one-quarter of their plate with lean protein, and varying the sources of protein
• Filling one-quarter of their plate with grains, making half of the grains whole grains

3. To describe the associations between demographic variables (ethnicity, education, household income, and home environment) and Gen Zs perceptions and knowledge of the DGA

Could this study be right for you?

18 to 28 years old

Live in the US

English speaker

Have access to a device that supports Zoom

Age Range

18 - 28 years

Contact Information

United States

Livia Schorn or Rhea Umrani

umrani.2@buckeyemail.osu.edu; schorn.5@buckeyemail.osu.edu

614-814-0866

Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Purpose

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

 

In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months. 

Could this study be right for you?

Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)

Must have not had a CT scan in the past 12 months

HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study

Able to understand and provide informed consent

Possess a smart phone that can browse the web

Not receiving any other smoking cessation interventions currently or within the prior 30 days

Female volunteers cannot be pregnant, lactating, or breast-feeding

Age Range

45 - 80 years

Contact Information

Columbus, OH

Zachary Dohar

Zachary.Dohar@osumc.edu

614-814-0377

Official Title A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa

Purpose

This study is being done to see how well remibrutinib works for people who have hidradenitis suppurativa

 

Could this study be right for you?

• Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
• Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
• Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
• Subject must not be taking anticoagulant medication (ex. warfarin) or dual anti-platelet therapy (ex. acetylsalicylic acid + clopidogrel)

Age Range

18 years and up

Contact Information

Elizabeth Begle

elizabeth.begle@osumc.edu

614-293-9306

Official Title AN OBSERVATIONAL, LONG-TERM SAFETY STUDY OF TZIELD® (TEPLIZUMAB-MZWV) IN PATIENTS WITH STAGE 2 TYPE 1 DIABETES

Purpose

The objective of the study is to test the safety and efficacy of TZIELD over the course of 10 years in patients with Stage 2, Type 1 Diabetes, as well as the prevention of Stage 3, Type 1 Diabetes. 

Could this study be right for you?

Inclusion Criteria:

TZIELD-Exposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
− Day 1: 65 μg/m²
− Day 2: 125 μg/m²
− Day 3: 250 μg/m²
− Day 4: 500 μg/m²
− Days 5 through 14: 1,030 μg/m² per day
− Cumulative dose is approximately 11,240 μg/m²

2. Appropriate written informed consent/assent as applicable for the age of the patient

TZIELD-Unexposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD
2. Appropriate written informed consent/assent as applicable for the age of the patient

Exclusion Criteria:
1. Patients who initiated TZIELD treatment more than 6 months prior to enrollment
2. Patients who had participated in a previous clinical trial for TZIELD
3. Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled.

Age Range

18 - 70 years

Contact Information

CarePoint East, CarePoint Dublin

Zack Lauderback

zackary.lauderback@osumc.edu

614-814-1055

Official Title Biomechanical Metrics of Movement Relative to Total Knee Arthroplasty

Purpose

This study aims to understand how a total knee replacement surgery (TKR) affects muscle function and movement in the lower body. It focuses on four key areas:

1. Examining how TKR changes the way muscles work in the lower body.

2. Exploring how these muscle changes relate to the forces people experience when walking and doing daily activities after surgery.

3. Connecting muscle function to how well patients feel and move after TKR.

4. Identifying different types of TKR patients based on their physical traits, movement patterns, and medical history to see how they compare.

Could this study be right for you?

• Must be scheduled to receive a total knee replacement within the next 2 months
• Have a body mass index (BMI) < 40
• Do not require the use of a cane or other assistive device when walking, climbing stairs, and getting up from a chair

Exclusion criteria varies; please contact Study Coordinator for more information

Age Range

18 years and up

Contact Information

Science Village (1381 Kinnear Rd Columbus, OH, 43212)

Kathryn Blessinger

blessinger.1@osu.edu

Official Title Effects of Acute and Chronic Ketone Ester Consumption on Exercise Tolerance and Cardiac Function in Subjects with Diabetes

Purpose

This placebo-controlled study is being done to evaluate the effects of a ketone ester drink on exercise performance and heart health in a group of subjects diagnosed with type 2 diabetes.

Could this study be right for you?

There are additional exclusion criteria, study staff will screen fully before enrollment.

Age Range

18 - 80 years

Contact Information

Center for Imaging Excellence, 2050 Kenny Road

Debbie Scandling

debbie.scandling@osumc.edu

614-688-5623

Official Title Lifestyle solutions to postprandial hypotension in spinal cord injury

Purpose

To test if a low-glycemic diet and electrical stimulation of leg muscles can improve blood pressure control after eating.

Could this study be right for you?

• Spinal cord injury sustained at least 1-year ago
• Level of injury between C4 and T10
• Use of wheelchair for majority of daily activities

Age Range

18 years and up

Contact Information

Columbus, OH

Raquel Minarsch

Raquel.Minarsch@osumc.edu